Last reviewed · How we verify
Estradiol Propionate (estradiol dipropionate)
Estradiol Propionate (generic name: estradiol dipropionate) is a Estrogen drug. It is currently in unknown development.
Estradiol propionate works by binding to estrogen receptors in the body, mimicking the effects of the naturally occurring hormone estrogen.
Estradiol Propionate, also known as estradiol dipropionate, is a synthetic estrogen medication. It is a small molecule that works by binding to estrogen receptors in the body, mimicking the effects of the naturally occurring hormone estrogen. However, due to the lack of available information, its specific target and indications are unknown. The commercial status of estradiol propionate is also unclear, with no information available on its patent status or generic manufacturers. As a result, its safety considerations and pharmacokinetic properties, such as half-life and bioavailability, remain unknown.
At a glance
| Generic name | estradiol dipropionate |
|---|---|
| Drug class | Estrogen |
| Therapeutic area | Metabolic |
| Phase | unknown |
Mechanism of action
Think of estrogen as a key that unlocks certain doors in your body, allowing it to function properly. Estradiol propionate is a synthetic version of that key, which can help unlock these doors and restore balance to your body's systems. This can be especially helpful for women who are experiencing hormonal imbalances or deficiencies.
Approved indications
Common side effects
Key clinical trials
- Menopausal Hormones and Sympathetic Activation (PHASE4)
- Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients (PHASE3)
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial (PHASE2)
- Romosozumab as an Adjunct to Physiologic Estrogen Replacement in Functional Hypothalamic Amenorrhea (PHASE3)
- Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors (PHASE1,PHASE2)
- A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors (PHASE1)
- Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment (PHASE2)
- Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Estradiol Propionate CI brief — competitive landscape report
- Estradiol Propionate updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Estradiol Propionate
What is Estradiol Propionate?
How does Estradiol Propionate work?
What is the generic name of Estradiol Propionate?
What drug class is Estradiol Propionate in?
What development phase is Estradiol Propionate in?
Related
- Drug class: All Estrogen drugs
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Metabolic
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing